www.biodiem.com Open in urlscan Pro
2400:b800:3:1::92  Public Scan

Form analysis
1 forms found in the DOM

POST http://biodiem.createsend.com/t/t/s/dkiyhy/

<form method="post" action="http://biodiem.createsend.com/t/t/s/dkiyhy/" onsubmit="return newsletter_check(this)">
  <h2>Join our email list!</h2>
  <p>Join our email distribution list to be updated with announcements.</p>
  <input id="fieldEmail" placeholder="Your email" class="newsletter-email" type="email" name="cm-dkiyhy-dkiyhy" size="30" required="">
  <input class="newsletter-submit" type="submit" value="Join">
</form>

Text Content

Forging a position as an innovative player in
infectious disease vaccines and therapies
 * Home
 * About
   * Company Overview
   * Board and management
   * News
 * Our Technology
   * Technology and Products
   * LAIV
   * BDM-I
   * About Our Disease Targets
 * Business Development
   * Partner Network
   * Licensing Strategy and Available Licenses
 * Investor Relations
   * Announcements
   * Financial Reports
   * Share trading
   * Videos
   * Corporate governance
   * Newsletters
   * Media
 * Contact Us
   * Corporate directory


OUR COMPANY


OUR TECHNOLOGY


INVESTOR RELATIONS

 


ABOUT US

BioDiem is an Australian biopharmaceutical company that is focused on developing
and commercialising vaccines and infectious disease therapies.

Our business model is to generate income from partnerships including with other
vaccine and infectious disease treatment companies through existing and new
licences to its LAIV vaccine and other technologies. We have an established
influenza vaccine licensing business. Our revenue comes from licence fees and
royalties on sales.

Our lead asset, the LAIV (Live Attenuated Influenza Virus) vaccine technology,
is used for production of seasonal and pandemic influenza vaccines and is given
intranasally. This technology is licensed currently to two commercial partners,
in India and China, and is licenced to the World Health Organisation as part of
the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. Nasovac-S™
is based on BioDiem’s technology and is already marketed in India and has WHO
Prequalification certification. In 2020 BioDiem’s Chinese licencee, Changchun
BCHT Biotechnology Co received marketing approval for their LAIV ‘flu vaccine
and launched DeFluvac in August 2020.

BioDiem’s subsidiary, Opal Biosciences Ltd – visit opalbiosciences.com.

BioDiem welcomes inquiries from shareholders and potential partners. Contact
info@biodiem.com

 


LATEST NEWS


 * 2024 AGM CEO PRESENTATION
   
   December 3, 2024
   
   2024 AGM CEO Presentation
   
   Read More


 * 2024 AGM CHAIRMAN’S ADDRESS
   
   December 3, 2024
   
   2024 AGM Chairman’s address
   
   Read More


JOIN OUR EMAIL LIST!

Join our email distribution list to be updated with announcements.

© Copyright 2014 BioDiem
 * Privacy Policy
 * Terms and conditions